Minapharm PharmaceuticalsCAI:MIPH -0.27%41 OCF Margin % is 14.44% as of Dec. 2025, which is 109% above its 10-year median of 6.90. GuruFocus rates CAI:MIPH with a GF Score™ of 41/100 and a GF Value™ of E£362.31 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 964 Drug Manufacturers companies, Minapharm Pharmaceuticals ranks worse than 56.22% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CAI:MIPH vs ZTS, UTHR, VTRS: OCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minapharm Pharmaceuticals OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Minapharm Pharmaceuticals's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minapharm Pharmaceuticals (CAI:MIPH) has a OCF Margin % of 14.44% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Minapharm Pharmaceuticals and its competitors. This is 109% above median its historical median of 6.90. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #542 out of 964 companies in the Drug Manufacturers industry, placing it in the top 56.2%.
Is Minapharm Pharmaceuticals' OCF Margin % too high?
Minapharm Pharmaceuticals' current OCF Margin % of 14.44% is 109% above median its 10-year median of 6.90. The Drug Manufacturers industry median OCF Margin % is 10.04. Minapharm Pharmaceuticals' value of 14.44% is 43.9% above this industry median. Based on the distribution chart, Minapharm Pharmaceuticals ranks #542 out of 964 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Minapharm Pharmaceuticals has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #542 out of 964 companies for OCF Margin %. This places Minapharm Pharmaceuticals in the lower half of its industry. The industry median OCF Margin % is 10.04. Minapharm Pharmaceuticals' value of 14.44% is 43.9% above this benchmark. While the company's 10-year median is 6.90 vs. the industry median of 10.04, Minapharm Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minapharm Pharmaceuticals's current OCF Margin % of 14.44% is 43.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Minapharm Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current OCF Margin % is 14.44%, which is 109% above median its own 10-year median of 6.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£362.31, compared to a current price of E£698.08 — trading 92.7% above its estimated fair value. The current OCF Margin % is 14.44%, which is 109% above median its 10-year median of 6.90 and 43.9% above the Drug Manufacturers industry median of 10.04. Minapharm Pharmaceuticals' overall GF Score™ is 41/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current OCF Margin % is 14.44% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£698.08 is trading 92.7% above its estimated GF Value™ of E£362.31.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
OCF Margin %: 14.44% (109% above median its 10-year median of 6.90)
GF Value™: E£362.31 vs. price of E£698.08 (92.7% above fair value)
Industry Position: 43.9% above the Drug Manufacturers median (#542 of 964)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
41GF Score
Get the complete analysis for CAI:MIPH
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 
